A pharma giant is moving past one patent cliff — but another is already looming

Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.

Source: [CNBC](https://www.cnbc.com/2026/10/30/novartis-remibrutinib-multiple-sclerosis.html)